GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MorphoSys AG (XSWX:MOR) » Definitions » Piotroski F-Score

MorphoSys AG (XSWX:MOR) Piotroski F-Score

: 0 (As of Today)
View and export this data going back to 1999. Start your Free Trial

Warning Sign:

Piotroski F-Score of 0 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

MorphoSys AG has an F-score of 1. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for MorphoSys AG's Piotroski F-Score or its related term are showing as below:

During the past 13 years, the highest Piotroski F-Score of MorphoSys AG was 6. The lowest was 0. And the median was 4.


MorphoSys AG Piotroski F-Score Historical Data

The historical data trend for MorphoSys AG's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MorphoSys AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.00 6.00 3.00 4.00 -

MorphoSys AG Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 3.00 5.00 4.00 -

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was -44.028 + -72.156 + -114.826 + 45.518 = CHF-185.5 Mil.
Cash Flow from Operations was -70.588 + -122.882 + 0 + 0 = CHF-193.5 Mil.
Revenue was 61.751 + 51.863 + 61.253 + 55.715 = CHF230.6 Mil.
Gross Profit was 40.957 + 44.351 + 46.756 + 41.895 = CHF174.0 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(2365.447 + 2209.22 + 2090.042 + 0 + 1910.964) / 5 = CHF2143.91825 Mil.
Total Assets at the begining of this year (Dec22) was CHF2,365.4 Mil.
Long-Term Debt & Capital Lease Obligation was CHF586.5 Mil.
Total Current Assets was CHF767.7 Mil.
Total Current Liabilities was CHF249.3 Mil.
Net Income was -125.542 + -241.002 + -118.434 + 325.115 = CHF-159.9 Mil.

Revenue was 42.443 + 60.963 + 92.223 + 80.594 = CHF276.2 Mil.
Gross Profit was 34.365 + 43.28 + 84.513 + 65.278 = CHF227.4 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(2660.237 + 2515.273 + 2572.688 + 0 + 2365.447) / 5 = CHF2528.41125 Mil.
Total Assets at the begining of last year (Dec21) was CHF2,660.2 Mil.
Long-Term Debt & Capital Lease Obligation was CHF679.4 Mil.
Total Current Assets was CHF1,074.7 Mil.
Total Current Liabilities was CHF274.7 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

MorphoSys AG's current Net Income (TTM) was -185.5. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

MorphoSys AG's current Cash Flow from Operations (TTM) was -193.5. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-185.492/2365.447
=-0.07841731

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-159.863/2660.237
=-0.06009352

MorphoSys AG's return on assets of this year was -0.07841731. MorphoSys AG's return on assets of last year was -0.06009352. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

MorphoSys AG's current Net Income (TTM) was -185.5. MorphoSys AG's current Cash Flow from Operations (TTM) was -193.5. ==> -193.5 <= -185.5 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=586.482/2143.91825
=0.27355614

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=679.414/2528.41125
=0.26871182

MorphoSys AG's gearing of this year was 0.27355614. MorphoSys AG's gearing of last year was 0.26871182. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=767.684/249.265
=3.07979058

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=1074.736/274.69
=3.91254141

MorphoSys AG's current ratio of this year was 3.07979058. MorphoSys AG's current ratio of last year was 3.91254141. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

MorphoSys AG's number of shares in issue this year was 0. MorphoSys AG's number of shares in issue last year was 0. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=173.959/230.582
=0.75443443

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=227.436/276.223
=0.82337821

MorphoSys AG's gross margin of this year was 0.75443443. MorphoSys AG's gross margin of last year was 0.82337821. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=230.582/2365.447
=0.09747925

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=276.223/2660.237
=0.10383398

MorphoSys AG's asset turnover of this year was 0.09747925. MorphoSys AG's asset turnover of last year was 0.10383398. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+0+0+0+1+0+0
=1

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

MorphoSys AG has an F-score of 1. It is a bad or low score, which usually implies poor business operation.

MorphoSys AG  (XSWX:MOR) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


MorphoSys AG Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of MorphoSys AG's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


MorphoSys AG (XSWX:MOR) Business Description

Address
Semmelweisstrasse 7, Planegg, BY, DEU, 82152
MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.

MorphoSys AG (XSWX:MOR) Headlines